Pharma BD Deal Intelligence

Pfizer Inc. / Merck KGaA

2014 · Co-Development · $2.9B · Complete

Announcement Sentiment

Positive

Outcome Score

Mixed — partial payoff, real shortfalls.

Pfizer partnered with Merck KGaA to co-develop and co-commercialize avelumab (anti-PD-L1) across multiple oncology indications in a deal worth up to $2.85B.

Key facts

Announced Nov 17, 2014
Closed Nov 17, 2014
Deal value $2.9B
Deal type Co-Development
Therapeutic area Oncology
Indications Merkel cell carcinoma, Urothelial carcinoma, Multiple solid tumors
Key assets avelumab (MSB-0010718C)
Mechanism Anti-PD-L1 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals